China is facing a growing public health challenge in the form of rising rates of overweight and obesity, which is creating new dynamics in the healthcare market and significant opportunities for the pharmaceutical industry. Currently, more than half of Chinese adults have a high body mass index, and it is estimated that by 2030 this figure could reach two-thirds of the adult population, or around 900 million people. This is driving demand for innovative medical solutions and effective treatments for weight management and metabolic health.
One company that has seen remarkable growth in this area is Novo Nordisk, the Danish pharmaceutical company behind weight management treatments such as Ozempic and Wegovy. The company has seen a significant increase in sales in China, with revenues set to grow by 13% to reach 18.5 billion Danish kroner (around $2.6 billion) by 2023. This growth occurred before Wegovy had completed its first full year on the market, following its launch in November 2024.
This phenomenon is part of a broader global trend in the market for weight management drugs, particularly GLP-1 receptor agonists, a class of drugs that help regulate appetite and blood sugar levels. These treatments represent a significant advance for people seeking to improve their well-being and metabolic health.
Growing global demand has strengthened Novo Nordisk’s market position. However, the competitive landscape may change in the coming years. Novo Nordisk’s patent protection for semaglutide, the active ingredient in Ozempic and Wegovy, expires in 2026. This could make it easier for other drugmakers to enter the market with potentially more accessible alternatives.
The Chinese pharmaceutical industry is already moving in this direction, with at least 15 companies developing their own versions of semaglutide. Both start-ups and large pharmaceutical companies are investing in this segment, which could diversify the supply and increase the accessibility of these treatments. This development reflects a wider trend in the Chinese pharmaceutical industry, which has shifted from a focus on producing generic drugs to developing innovative treatments with global impact.
Companies such as BeiGene and Junshi Biosciences have made significant progress in areas such as cancer treatment and immunotherapy, with some of their products even gaining approval in the US and Europe. The successful production and marketing of alternatives to semaglutide could further consolidate China’s role in the global pharmaceutical industry. Although China’s rising rates of overweight and obesity are the main driver of this trend, the healthcare growth opportunities are not limited to this market.
Other countries, such as India, are also experiencing an increase in demand for weight management treatments, driven by the growth of the middle class and changes in consumption patterns and lifestyles. For investors, this evolution in the global healthcare market represents a long-term opportunity with important implications for the pharmaceutical industry and the development of innovative treatments in emerging markets.
Disclaimer: The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Capital Strategies Limited or its related companies. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.
